Show simple item record

dc.contributor.authorVenugopal, B.
dc.contributor.authorPillai, Manon
dc.contributor.authorPowles, T.
dc.contributor.authorSavage, P.
dc.contributor.authorMichael, A.
dc.contributor.authorFife, K.
dc.contributor.authorKlair, B.
dc.contributor.authorPerrot, V.
dc.contributor.authorSzabados, B.
dc.date.accessioned2022-01-11T12:00:03Z
dc.date.available2022-01-11T12:00:03Z
dc.date.issued2021en
dc.identifier.citationVenugopal B, Pillai M, Powles T, Savage P, Michael A, Fife K, et al. Early Clinical Experience with Cabozantinib for Advanced Renal Cell Carcinoma in the UK: Real-World Treatment Pathways and Clinical Outcomes Clinical Genitourinary Cancer. Elsevier BV; 2021.en
dc.identifier.pmid34802966en
dc.identifier.doi10.1016/j.clgc.2021.09.005en
dc.identifier.urihttp://hdl.handle.net/10541/624945
dc.description.abstractBackground: Cabozantinib monotherapy is approved in the UK for patients with treatment-naïve intermediate- or poor-risk advanced renal cell carcinoma (aRCC), or patients who received prior vascular endothelial growth factor-targeted therapy. Data are limited on the real-world use of cabozantinib for aRCC. Patients and methods: CERES (NCT03696407) was a retrospective study of patients with aRCC who received cabozantinib through the UK managed access programme (MAP; August 2016-July 2017), at which time cabozantinib had European regulatory approval for second- or later-line use only. The study objectives were to characterize aRCC treatment patterns and evaluate cabozantinib effectiveness. Outcomes were stratified by cabozantinib treatment line, MAP treatment date (months 0-7 vs. 8-12) and (post hoc) Charlson Comorbidity Index (CCI; ≥ 6 vs. < 6). Results: Of 100 patients included, 99% had stage IV disease, 63% had a CCI ≥ 6 and 81% had an Eastern Cooperative Oncology Group Performance Status 0-1. Median (range) duration of follow-up was 10.8 (0.4-33.5) months. Cabozantinib was administered as second-line, third-line and fourth- or later-line in 41%, 31% and 28% of patients, respectively. Most patients (84%) initiated cabozantinib at 60 mg. Average (range) cabozantinib dose was 45.5 (19.6-59.8) mg/day; 66% of patients had ≥ 1 dose reduction. Disease progression was the most common reason for discontinuation (65.1%). Median (95% confidence interval) progression-free survival (PFS) and overall survival (OS) were 6.01 (5.16-7.85) and 10.84 (7.92-16.85) months, respectively. Overall response rate was 34.5%; disease control rate 70.1% and duration of response 6.9 (1.8-26.9) months. No significant differences in survival estimates were observed between treatment line or treatment date subgroups. Total CCI score ≤ 6 (vs. > 6) was associated with prolonged median PFS and OS. Conclusion: Cabozantinib demonstrated clinical activity in this UK real-world aRCC population. The results provide a benchmark for future real-world studies in aRCC.en
dc.titleEarly clinical experience with cabozantinib for advanced renal cell carcinoma in the UK: real-world treatment pathways and clinical outcomesen
dc.typeArticleen
dc.contributor.departmentBeatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, UKen
dc.identifier.journalClinical Genitourinary Canceren
dc.description.noteen]
refterms.dateFOA2022-04-12T09:07:58Z


Files in this item

Thumbnail
Name:
34802966.pdf
Size:
1.730Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record